BridgeBio commits $300K to Speak Foundation LGMD Centers of Excellence

BridgeBio partners with The Speak Foundation to fund expansion of patient-led LGMD Centers of Excellence. The program aims to improve specialized care coordination, research readiness, and access to emerging treatments for limb-girdle muscular dystrophy patients. BridgeBio is developing BBP-418 (ribitol) for LGMDR9.

Key facts

Filed: Oct 1, 2026, 09:00 PM
Event: Partnership / licensing deal
Direction: Neutral
Company: BBIOBridgeBio
Asset: acoramidis
Source: Company press release
Confidence: Sourced
commitment: $300,000 over two years

Source excerpt

The Speak Foundation Announces $300,000 BridgeBio Commitment to Advance Patient-Led LGMD Centers of Excellence The Speak Foundation Announces $300,000 BridgeBio Commitment to Advance Patient-Led LGMD Centers of Excellence News provided by The Speak Foundation Oct 01, 2026, 09:00 ET Share this article Share to X Share this article Share to X WASHINGTON , Oct. 1, 2026 /PRNewswire/ -- The Speak Foundation is pleased to announce a $300,000 commitment over two years from BridgeBio Pharma, Inc. to support and expand its national LGMD Centers of Excellence program, a patient-led initiative designed to strengthen specialized care, research readiness and access to emerging treatments for people living with limb-girdle muscular dystrophy. The patient-designed Centers of Excellence are intended to replace fragmented care with coordinated, specialized care. People with LGMD often must find local specialists on their own and explain a rare condition to clinicians unfamiliar with it. At an LGMD Center of Excellence, patients can connect with clinicians experienced in neuromuscular disease who can coordinate care across specialties such as neurology, cardiology and pulmonology and provide guidance on what to monitor and avoid. Expanding the network aims to bring expert LGMD care closer to more families and reduce geographic gaps in access, while bringing together leading LGMD clinical care around shared standards of care, patient education, research participation and collaboratio

Company press release